DMAC - DiaMedica Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

DMAC is currently covered by 2 analysts with an average price target of $19.03. This is a potential upside of $10.4 (120.51%) from yesterday's end of day stock price of $8.63.

DiaMedica Therapeutics's activity chart (see below) currently has 26 price targets and 31 ratings on display. The stock rating distribution of DMAC is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 22.62% with an average time for these price targets to be met of 193.71 days.

Highest price target for DMAC is $14, Lowest price target is $12, average price target is $13.

Most recent stock forecast was given by MATTHEW CAUFIELD from HC WAINWRIGHT on 15-Aug-2025. First documented stock forecast 03-Jan-2019.

Currently out of the existing stock ratings of DMAC, 5 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$12

$3.37 (39.05%)

$12

3 months 14 days ago
(15-Aug-2025)

2/6 (33.33%)

$5.97 (99.00%)

315

Buy

$14

$5.37 (62.22%)

4 months 11 days ago
(18-Jul-2025)

0/2 (0%)

$9.82 (234.93%)

Buy

$6

$-2.63 (-30.48%)

$6

1 years 3 months 13 days ago
(16-Aug-2024)

3/4 (75%)

$2.4 (66.67%)

403

Buy

$8

$-0.63 (-7.30%)

$8

1 years 7 months 5 days ago
(24-Apr-2024)

3/6 (50%)

$5.55 (226.53%)

638

Buy

4 years 2 months 2 days ago
(27-Sep-2021)

0/1 (0%)

$27.58 (264.68%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is DMAC (DiaMedica Therapeutics) average time for price targets to be met?

On average it took 193.71 days on average for the stock forecasts to be realized with a an average price target met ratio 22.62

Which analyst has the current highest performing score on DMAC (DiaMedica Therapeutics) with a proven track record?

ALEXANDER NOWAK

Which analyst has the current lower performing score on DMAC (DiaMedica Therapeutics) with a proven track record?

JASON MCCARTHY

Which analyst has the most public recommendations on DMAC (DiaMedica Therapeutics)?

Alexander Nowak works at CRAIG HALLUM and has 22 price targets and 7 ratings on DMAC

Which analyst is the currently most bullish on DMAC (DiaMedica Therapeutics)?

Etzer Darout with highest potential upside - $16.37

Which analyst is the currently most reserved on DMAC (DiaMedica Therapeutics)?

Francois Brisebois with lowest potential downside - -$2.63

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?